A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Clinical trial NCT06659549 · RECRUITING

Trial details

NCT number: NCT06659549
Sponsor: Galimedix Therapeutics Inc
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Geographic Atrophy of the Macula

Start date: 2025-01-10
Primary completion: 2027-03-30
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.